{"id":107261,"date":"2026-04-15T03:49:07","date_gmt":"2026-04-15T03:49:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/arla-foods-ingredients-targets-glp-1-companion-nutrition-at-vitafoods-europe\/"},"modified":"2026-04-15T03:49:07","modified_gmt":"2026-04-15T03:49:07","slug":"arla-foods-ingredients-targets-glp-1-companion-nutrition-at-vitafoods-europe","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/arla-foods-ingredients-targets-glp-1-companion-nutrition-at-vitafoods-europe\/","title":{"rendered":"Arla Foods Ingredients Targets GLP-1 Companion Nutrition at Vitafoods Europe"},"content":{"rendered":"
\n

COPENHAGEN, Denmark, April 14, 2026 (GLOBE NEWSWIRE) — Arla Foods Ingredients<\/a> has developed high-protein, nutrient-dense application concepts for users of GLP-1 anti-obesity medications, which it will showcase at Vitafoods Europe (5th<\/sup>-7th<\/sup> May 2026 in Barcelona).<\/p>\n

Originally developed to treat diabetes, GLP-1 receptor agonists have re-shaped the weight management market. In 2025, 11% of consumers globally [1]<\/a> and 18% in the US [2]<\/a> who were actively trying to lose weight reported using them, with uptake expected to rise as availability expands, tablet formats emerge and prices fall [3]<\/a>.<\/p>\n

However, GLP-1 use is associated with side effects: lean muscle loss may reach 40% of total mass lost, versus around 25% with traditional interventions [4<\/a>, 5<\/a>, 6<\/a>], while up to 76% of GLP-1 consumers report gastric discomfort and reduced appetite [7]<\/a>.<\/p>\n

To help manufacturers address these needs, Arla Foods Ingredients has developed high-protein concepts with Nutrilac\u00ae<\/sup> and Lacprodan\u00ae<\/sup> BLG-100, delivering all essential amino acids for muscle health in nutrient-dense formats, and incorporating probiotics \/ cultures from Novonesis to support digestive well-being.\u00a0 <\/p>\n

The range includes great-tasting formats for reduced appetites: <\/p>\n